Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 30, 2025 09:56 ET | Source: Barinthus Biotherapeutics

Barinthus Biotherapeutics to Combine with Clywedog Therapeutics to Target Metabolic and Autoimmune Diseases

GERMANTOWN, MD and ALTRINCHAM, UK, Sept. 30, 2025 (GLOBE NEWSWIRE) -- The combined company, Clywedog Therapeutics, will bring a portfolio that includes three differentiated, clinical stage product...
September 30, 2025 08:00 ET | Source: Barinthus Biotherapeutics

Barinthus Biotherapeutics to Combine with Clywedog Therapeutics to Target Metabolic and Autoimmune Diseases

The combined company, Clywedog Therapeutics, will bring a portfolio that includes three differentiated, clinical stage product candidates which are being studied for the prevention/reversal of Type 1...
October 01, 2024 08:00 ET | Source: Barinthus Biotherapeutics

Barinthus Bio Completes Enrollment for Phase 2b HBV003 Clinical Trial in Chronic Hepatitis B and Phase 1 PCA001 Clinical Trial in Prostate Cancer

Barinthus Bio Completes Enrollment for Phase 2b HBV003 Clinical Trial in Chronic Hepatitis B and Phase 1 PCA001 Clinical Trial in Prostate Cancer
May 01, 2024 07:00 ET | Source: Barinthus Biotherapeutics

Barinthus Bio Names Experienced Physician, Leon Hooftman, M.D., as Chief Medical Officer

Barinthus Bio Names Experienced Physician, Leon Hooftman, M.D., as Chief Medical Officer.
April 18, 2024 16:10 ET | Source: Barinthus Biotherapeutics

Barinthus Bio Announces Topline Data from Phase 1b/2 APOLLO Trial of VTP-200 in Persistent High-Risk Human Papillomavirus (HPV) Infections

Barinthus Biotherapeutics plc (NASDAQ: BRNS), formerly Vaccitech plc, today announced topline final data from the APOLLO trial (also known as HPV001).